Law360, Washington (December 07, 2011, 4:54 PM ET) -- Bayer Healthcare Pharmaceuticals Inc. sought to persuade the Federal Circuit on Wednesday that it has a valid case to block generics makers from introducing a version of its oral contraceptive Yasmin, saying its patent covers all uses of the drug.
In September 2010, a New York federal judge ruled in favor of Watson Laboratories Inc. and Sandoz Inc. in Bayer's Hatch-Waxman Act suit, saying the disputed claim of U.S. Patent 5,569,652 does not cover a use approved by the U.S. Food and Drug Administration.
Bayer argued...
Bayer Battles Generic Yasmin Hopeful In Fed. Circ.
To view the full article, take a free trial now.
